GlassScriptPhysician profile
Juan J Olivero
NPI 1194774448
$504.64
in general payments reported to CMS, 2019-2025
16 companies · $22.81 in 2025
The $22.81 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $27.42 · 2021: $46.85 · 2022: $127 · 2024: $176 · 2025: $22.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $174 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $174.16 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $168.82 | 2020-2022 | |
| Melinta Therapeutics, LLC | $118.07 | 2024 | Rezzayo, Kimyrsa |
| Amgen INC. | $43.72 | 2019-2025 | Tavneos |
| Mallinckrodt Enterprises LLC | $37.04 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $34.79 | 2019-2021 | |
| Nxstage Medical, INC. | $33.28 | 2024 | |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Shire North American Group INC | $16.67 | 2019 | |
| Veloxis Pharmaceuticals, INC. | $16.44 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.20 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Olivero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.